

**Title:** Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories.

**Authors:** Konrad Krawczyk<sup>1\*</sup>, Matthew Raybould<sup>2</sup>, Aleksandr Kovaltsuk<sup>2</sup>, Charlotte M. Deane<sup>2</sup>

<sup>1</sup> NaturalAntibody, Hamburg, Germany

<sup>2</sup> Oxford University Department of Statistics, Oxford, UK

\*Correspondence to [konrad@naturalantibody.com](mailto:konrad@naturalantibody.com)

**Abstract:** Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies.

## Introduction

Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response. This great diversity can now be queried using Next Generation Sequencing (NGS) of B-cell receptor repertoires, enabling rapid collection of millions of antibody sequences from any given individual<sup>1-3</sup>.

The sequence of a protein, such as an antibody, is one of the chief vehicles to characterize the molecule in the patent claim<sup>4</sup>. Natural sequences however cannot be patented in the USA<sup>5</sup>. The seminal rulings in the Mayo and Prometheus cases set the precedent to reject patent claims to naturally occurring DNA sequences and it was subsequently extended to include all products of nature<sup>6,7</sup>. The large numbers of antibody sequences now becoming available in the public domain raise the possibility of natural sequences being found that are identical to commercial sequences<sup>5</sup>.

This is especially pertinent in the face of large-scale organized efforts to make naturally sourced antibody NGS data<sup>8</sup> and analytics<sup>9,10</sup> more accessible<sup>11</sup>. Specifically, we recently created the Observed Antibody Space (OAS) database that curates the NGS antibody data from public archives and makes them available for easy processing<sup>12</sup>. OAS currently holds ~1b (~960m heavy chain and ~60m light chain) sequences from 60 independent studies. The datasets cover multiple organisms (human, mouse, rabbit, camel etc.), individuals, immune states (non-immunized, immunized etc.) and include the deep sequencing of the totality of adaptive repertoires of mice<sup>13</sup> (246m sequences) and humans<sup>3</sup> (318m sequences). Here we quantify how close a sequence match to current Clinical Stage Therapeutic (CST) antibody sequences we can find in OAS.

## Results

We used a set of 242 CST antibody sequences<sup>14</sup>. These are all sequences that have passed Phase I of clinical trials. We separately aligned the CST variable regions (VH or VL), combination of the three Complementarity Determining Regions (CDRs) from VH or VL and CDR-H3s to all the sequences in OAS (see methods). We performed the search across all organisms, individuals and immune states to be comprehensive and to reflect the myriad antibody types (humanized, fully human, chimeric or mouse<sup>15</sup>). The individual identities of the CSTs with respect to the best match from OAS are given in Figure 1 and Table 1 and their distributions are plotted in Figure 2. The aligned sequences are available in the Supplementary Material and on our website <http://naturalantibody.com/therapeutics>.

### Analysis of Clinical Stage Therapeutic sequence matches to naturally sourced NGS datasets.

The best sequence identity matches of CST variable regions to naturally sourced NGS datasets in OAS are given in Figure 1A. Ninety (37.1%) CST heavy chains have matches within OAS of  $\geq 90\%$  sequence identity (seqID), with 18 (7.4%)  $\geq 95\%$  seqID. We find 158 (65.2%) therapeutic light chains with  $\geq 90\%$  seqID to an OAS sequence, with 96 (39.7%)  $\geq 95\%$  seqID, and 28 (11.5%) with 100% seqID. For 16 (6.6%) of the CSTs we find both heavy and light chain matches  $\geq 95\%$  seqID. In the most extreme case, Enfortumab, we were able to find both heavy and light chain matches of 98% seqID (the differences are H38:N-S, H88:S-Y, L37:G-S, L52:F-L where the first amino acid comes from Enfortumab and the second from an OAS sequence).

The largest discrepancy between the CSTs and any given natively-expressed antibody is typically concentrated in the CDR regions that determine antigen complementarity<sup>16</sup>. It remains unclear, however, the extent to which the highly mutable CDR loops of engineered therapeutics differ from those that are expressed naturally. We searched for the best CST matches to the CDR regions in OAS. The search was performed using IMGT-defined CDR triplets from the heavy or light chain, disregarding the framework region (Table 1, Figure 1B and Figure 2). We find 46 (19.0%) of CST heavy chain CDR regions to have matches to an OAS CDR region with  $\geq 90\%$  seqID, 15 (6.1%) with  $\geq 95\%$  seqID and 4 (1.6%) with 100% seqID. There were 156 (64.4%) CST light CDR regions with  $\geq 90\%$  seqID to an OAS CDR region, with 110 (45.4%)  $\geq 95\%$  seqID, and 90 (37.1%) with 100% seqID. We found perfect matches for both light and heavy chain CDRs in two CSTs, Obiltoxaximab and Zanolimumab.

Of the six Complementarity Determining Regions, CDR-H3 is the most sequence and structurally diverse<sup>17,18</sup>. Due to its key role in binding, it is subjected to extensive antibody engineering<sup>19,20</sup>. We checked how likely it is to find CST-derived CDR-H3s in naturally sourced sequences. To assess this, we searched for the best CST CDR-H3 matches in OAS, regardless of the framework region and remaining CDRs (Table 1, Figure 2). Of our 242 CST CDR-H3s, we found 54 perfect matches in OAS. The perfect matches tended to be for shorter CDR-H3s, however some longer loops with perfect matches were also found (see Supplementary Section 1). Twenty-nine perfect matches were found in the recent deep sequencing dataset of Briney et al. (2019)<sup>3</sup>, suggesting that a single comprehensive NGS study can cover a significant amount of CDR-H3 diversity. Forty-seven perfect matches were found in OAS datasets other than that of Briney et al. (2019), showing that certain artificial CDR-H3 sequences can be independently observed in naturally sourced NGS. Twenty-two CDR-H3 matches were found in both Briney et al. data and other OAS datasets. These 22 shared sequences come from 9 humanized and 13 fully human CSTs. The 54 perfect CDR-H3 matches were distributed among all antibody types,

with 23 humanized, 22 fully human, 8 chimeric and 1 mouse (21.9%, 22.0%, 22.8% and 50.0% of each category, respectively). These results show that, despite the large theoretical sequence space accessible to the CDR-H3 region<sup>3</sup>, therapeutically-exploitable CDR-H3 loops are found in just ~960m heavy chain sequences from 60 NGS studies (see Supplementary Section 2). This convergence, coupled with the fact that CDR-H3 loops often mediate antibody specificity<sup>21</sup> and binding affinity, could suggest intrinsically driven biases in antigen recognition<sup>22</sup>, independent of artificial discovery methods.

### **Stratifying the best CST matches in OAS by antibody type.**

The quality of the variable region match we could find for any given CST sequence appears to be highly dependent on the discovery platform/antibody type. Figure 3 suggests that antibodies produced via more artificial protocols such as humanization have lower variable region sequence identities to sequences in OAS from those of fully human molecules. For the majority of the fully human sequences we find matches of 90% seqID or better whereas matches to the majority of humanized molecules fall below 90% seqID (Figure 3). Chimeric antibodies appear to have seqID values intermediate between the two classes (Figure 3).

The CST antibody type also reflects the organism that produced the best NGS seqID match. Of the 100 fully human CSTs, the 90 (90.0%) most similar heavy chains, 100 (100.0%) most similar light chains, and 55 (55.0%) most similar CDR-H3 loops come from human-sourced NGS. Of the 105 humanized antibodies, 82 (78.0 %) of heavy chains, and 79 (75.2%) of light chains found closest matches in human-sourced NGS, while 71 (67.6%) of the best CDR-H3s matches were identified in mouse-sourced NGS. This further reflects the dominance of CDR-H3 in binding, as therapeutic companies tend to graft this loop from binding mouse antibodies to transfer specificity and binding affinity. It also suggests that data-mining a dataset such as OAS could provide a more accurate measure of antibody 'humanness' than our current metrics<sup>23,24</sup>.

### **Discussion**

Our results demonstrate that despite the theoretically large diversity allowed to antibodies<sup>3,25</sup>, there exists a nontrivial convergence between artificially developed CSTs and naturally sourced NGS sequences. The closest NGS matches to CSTs were sourced from 48 of the 60 (80.0%) independent datasets available in OAS indicating that finding a close match to at least one CST is likely in most NGS datasets.

It was previously suggested that such an overlap could cause issues in claiming patents on therapeutic antibodies<sup>5</sup>. Until a legal opinion on the subject is available, it will remain unclear if NGS data poses potential problems for the patentability of monoclonal antibodies. Firstly, sequence is one of the main ways to characterize a molecule in a patent claim but by itself it does not offer information about its cognate antigen and therapeutic action. Such information however is crucial in patent application to demonstrate novelty of the invention<sup>4</sup>. NGS studies produce copious amounts of sequences but they do not alone relate them to any target molecule. Secondly, the antibody variable region is a product of two polypeptide chains (heavy and light) and its function is intimately related to this combination. Currently the majority of available NGS datasets report heavy and light chains separately. Thirdly, NGS outputs are known to have high error rates<sup>26</sup> and lastly, it is unclear how close a sequence-identity match to a publicly available sequence or its portion (such as CDR-H3) would cause issues in establishing the inventiveness of a sequence. For instance, there exist only four pairs of CSTs with heavy chain sequence identities of more than 94% (see supplementary section 3). In three of such high sequence-identity pairs, both sequences come from the same company and the

fourth is the original patent-expired antibody and its derivative. This is compared to 18 therapeutic heavy chains with matches to OAS better than 95%.

In light of ongoing efforts to further consolidate antibody NGS data and make it more accessible, it follows that finding therapeutic candidate sequences in published NGS datasets will become easier<sup>11,27</sup>.

## Methods.

We used the Observed Antibody Space database as the source of NGS sequences. Since its first release, the database has been expanded by four more datasets, most notably the recent deep sequencing of human antibody repertoire by Briney et al. 2019<sup>3</sup>. We employed the processed consensus sequences from Briney et al., removing any sequences with stop codons as these were deemed unproductive.

We used the 242 antibodies from Raybould et al.<sup>14</sup> as the source of Clinical Stage Therapeutic (CST) antibodies. We numbered the CST sequences according to the IMGT<sup>28</sup> scheme using ANARCI<sup>29</sup>. The CST sequences were classified into four groups, based on their International Nonproprietary Names<sup>15,30</sup>. Sequences with names containing '-xizumab', '-ximab' or '-monab' were labeled as 'chimeric'. Sequences not matching this criterion but containing '-zumab' in their name were classified as 'humanized'. Sequences that contained only '-umab' in their name were labeled as 'fully human'. Two mouse antibodies (Abagovomab and Racotumomab), were labeled as 'mouse'.

We separately aligned the heavy chain, light chain, the combination of the three heavy or light chains IMGT-defined CDRs and the IMGT-defined CDR-H3 of CSTs to each of the sequences in OAS<sup>12</sup>. We note a match if an IMGT position in a 'query' CST is also found in a 'template' sequence from OAS, and they have the same amino acid residue. For the full sequence alignments, the number of matches is divided by the length of the query and by the length of the template, producing two sequence identities. The final sequence identity is the average between these two. Calculating the sequence identity in this way prevents the scenario when one sequence is a substring of another, creating an artificially high sequence identity with a large length discrepancy. The CDR alignments were performed when the IMGT-defined loop lengths matched. The aligned sequences are available in the supplementary section 4 and through an interactive version of Figure 1 and Table 1 accessible at <http://naturalantibody.com/therapeutics>.

## Disclosure Statement.

The authors report no conflict of interest


## References

1. Miho E, Yermanos A, Weber CR, Berger CT, Reddy ST, Greiff V. **Computational Strategies for Dissecting the High-Dimensional Complexity of Adaptive Immune Repertoires**. *Front. Immunol.* 2018; 9:224; PMID: 29515569; <http://dx.doi.org/10.3389/fimmu.2018.00224>
2. Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR. **The promise and challenge of high-throughput sequencing of the antibody repertoire**. *Nat. Biotechnol.* 2014; 32(2):158-68; PMID: 24441474; <http://dx.doi.org/10.1038/nbt.2782>
3. Briney B, Inderbitzin A, Joyce C, Burton DR. **Commonality despite exceptional diversity in the baseline human antibody repertoire**. *Nature* 2019; PMID: 30664748; <http://dx.doi.org/10.1038/s41586-019-0879-y>
4. Germinario C, Bertoli S, Rampinelli P, Cini M. **Patentability of antibodies for therapeutic use in Europe**. *Nat. Biotechnol.* 2018; 36(5):402-405; PMID: 29734309; <http://dx.doi.org/10.1038/nbt.4134>
5. Ponraj P. **Next-generation sequencing may challenge antibody patent claims**. *Nature* 2018; 557(7704):166; PMID: 29743696; <http://dx.doi.org/10.1038/d41586-018-05065-5>
6. Harrison C. **Patent watch**. *Nat. Rev. Drug Discov.* 2012; 11:344–345; <http://dx.doi.org/10.1038/nrd3735>
7. Harrison C. **Isolated DNA patent ban creates muddy waters for biomarkers and natural products**. *Nat. Rev. Drug Discov.* 2013; 12(8):570-1; PMID: 23903213; <http://dx.doi.org/10.1038/nrd4084>
8. Cowell LG. **VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements**. *Front. Immunol.* 2018; 9:976; PMID: 29867956; <http://dx.doi.org/10.3389/fimmu.2018.00976>
9. Krawczyk K, Kelm S, Kovaltsuk A, Galson JD, Kelly D, Trück J, Regep C, Leem J, Wong WK, Nowak J, et al. **Structurally mapping antibody repertoires**. *Front. Immunol.* 2018; 9:1698; PMID: 30083160; <http://dx.doi.org/10.3389/fimmu.2018.01698>
10. López-Santibáñez-Jácome L, Avendaño-Vázquez SE, Flores-Jasso CF. **The pipeline repertoire of Ig-Seq analysis**. *PeerJ* 2018; <http://dx.doi.org/10.7287/peerj.preprints.27444v1>
11. Rubelt F, Busse CE, Bukhari SAC, Bürckert JP, Mariotti-Ferrandiz E, Cowell LG, Watson CT, Marthandan N, Faison WJ, Hershberg U, et al. **Adaptive Immune Receptor Repertoire Community recommendations for sharing immune-repertoire sequencing data**. *Nat. Immunol.* 2017; 18(12):1274-1278; PMID: 29144493; <http://dx.doi.org/10.1038/ni.3873>
12. Kovaltsuk A, Leem J, Kelm S, Snowden J, Deane CM, Krawczyk K. **Observed Antibody Space: A Resource for Data Mining Next-Generation Sequencing of Antibody Repertoires**. *J. Immunol.* 2018; 201(8):2502-2509; PMID: 30217829; <http://dx.doi.org/10.4049/jimmunol.1800708>
13. Greiff V, Menzel U, Miho E, Weber C, Riedel R, Cook S, Valai A, Lopes T, Radbruch A, Winkler TH, et al. **Systems Analysis Reveals High Genetic and Antigen-Driven Predetermination of Antibody Repertoires throughout B Cell Development**. *Cell Rep.* 2017; 19(7):1467-1478; PMID: 28514665; <http://dx.doi.org/10.1016/j.celrep.2017.04.054>
14. Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J,


- Deane CM. **Five computational developability guidelines for therapeutic antibody profiling.** Proc. Natl. Acad. Sci. USA 2019; 116(10):4025-4030; PMID: 30765520; <http://dx.doi.org/10.1073/pnas.1810576116>
15. Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. **Biophysical properties of the clinical-stage antibody landscape.** Proc. Natl. Acad. Sci. USA 2017; 114(5):944-949; PMID: 28096333; <http://dx.doi.org/10.1073/pnas.1616408114>
  16. Sela-Culang I, Kunik V, Ofra Y. **The structural basis of antibody-antigen recognition.** Front. Immunol. 2013; 4:302; PMID: 24115948; <http://dx.doi.org/10.3389/fimmu.2013.00302>
  17. MacCallum RM, Martin AC, Thornton JM. **Antibody-antigen interactions: contact analysis and binding site topography.** J Mol Biol 1996; 262(5):732-45; PMID: 8876650; <http://dx.doi.org/10.1006/jmbi.1996.0548>
  18. Krawczyk K, Dunbar J, Deane CM. **Computational Tools for Aiding Rational Antibody Design.** Methods in molecular biology (Clifton, N.J.) 2017; 1529:399-416; PMID: 27914064; [http://dx.doi.org/10.1007/978-1-4939-6637-0\\_21](http://dx.doi.org/10.1007/978-1-4939-6637-0_21)
  19. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellenhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. **Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.** J. Mol. Biol. 2000; 296(1):57-86; PMID: 10656818; <http://dx.doi.org/10.1006/jmbi.1999.3444>
  20. De Kruif J, Boel E, Logtenberg T. **Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions.** J. Mol. Biol. 1995; 248(1):97-105; PMID: 7731047; <http://dx.doi.org/10.1006/jmbi.1995.0204>
  21. Tsuchiya Y, Mizuguchi K. **The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops.** Protein. Sci. 2016; 25(4):815-25; PMID: 26749247; <http://dx.doi.org/10.1002/pro.2874>
  22. Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM. **Conformations of the third hypervariable region in the VH domain of immunoglobulins.** J. Mol. Biol. 1998; 275(2):269-94; PMID: 9466909; <http://dx.doi.org/10.1006/jmbi.1997.1442>
  23. Abhinandan KR, Martin ACR. **Analyzing the “Degree of Humanness” of Antibody Sequences.** J. Mol. Biol. 2007; 369(3):852-62; PMID: 17442342; <http://dx.doi.org/10.1016/j.jmb.2007.02.100>
  24. Choi Y, Hua C, Sentman CL, Ackerman ME, Bailey-Kellogg C. **Antibody humanization by structure-based computational protein design.** MAbs 2015; 7(6):1045-57; PMID: 26252731; <http://dx.doi.org/10.1080/19420862.2015.1076600>
  25. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, Ni I, Mei L, Sundar PD, Day GMR, et al. **Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire.** Proc. Natl. Acad. Sci. USA 2009; 106(48):20216-21; PMID: 19875695; <http://dx.doi.org/10.1073/pnas.0909775106>
  26. Kovaltsuk A, Krawczyk K, Kelm S, Snowden J, Deane CM. **Filtering Next-Generation Sequencing of the Ig Gene Repertoire Data Using Antibody Structural Information.** J. Immunol. 2018; 201(12):3694-3704; PMID: 30397033; <http://dx.doi.org/>

10.4049/jimmunol.1800669


27. Breden F, Luning Prak ET, Peters B, Rubelt F, Schramm CA, Busse CE, Vander Heiden JA, Christley S, Bukhari SAC, Thorogood A, et al. **Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data**. *Front. Immunol.* 2017; 8:1418; PMID: 29163494; <http://dx.doi.org/10.3389/fimmu.2017.01418>
28. Lefranc M, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G. **IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains**. *Dev. Comp. Immunol.* 2003; 27(1):55-77; PMID: 12477501; [http://dx.doi.org/10.1016/S0145-305X\(02\)00039-3](http://dx.doi.org/10.1016/S0145-305X(02)00039-3)
29. Dunbar J, Deane CM. **ANARCI: Antigen receptor numbering and receptor classification**. *Bioinformatics* 2015; 32(2):298-300; PMID: 26424857; <http://dx.doi.org/10.1093/bioinformatics/btv552>
30. Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RGE, Hötzel I, Popplewell AG, Parren PWHI, Enzelberger M, Rademaker HJ, et al. **The INNs and outs of antibody nonproprietary names**. *MAbs* 2016; 8(1):1-9; PMID: 26716992; <http://dx.doi.org/10.1080/19420862.2015.1114320>



**Figure 1. Best sequence identity matches to Clinical Stage Therapeutics (CST) in naturally sourced NGS datasets. A)** Heavy and light chain variable regions of 242 CST sequences from Raybould et al.<sup>14</sup> aligned to variable region sequences in OAS<sup>12</sup>. **B)** Heavy and light chain IMGT CDR regions of 242 CSTs aligned to IMGT CDR regions in OAS. Fully human sequences are denoted by blue dots, humanized by green and chimeric by magenta. The two mouse sequences are shown in red. Interactive versions of these charts are available at <http://naturalantibody.com/therapeutics>.



**Figure 2. Distribution of sequence identity matches of Clinical Stage Therapeutics (CSTs) to naturally-sourced NGS.** The violin plots show the distribution of sequence identities of the variable heavy (VH) and light (VL) chains, heavy and light CDR regions and CDR-H3 of CSTs to best matches in OAS.



**Figure 3. Sequence identity matches of Clinical Stage Therapeutic (CST) variable regions to naturally sourced NGS datasets stratified by CST antibody type.** CST **A)** heavy chain and **B)** light chain identities to NGS sequences in OAS stratified by Fully Human, Chimeric and Humanized antibody types. The two mouse molecules were omitted as too small a sample.



**Table 1. Best sequence identities of Clinical Stage Therapeutic (CST) antibodies to sequences found in public NGS repositories.** Sequence identities are given for the best alignment of a sequence from a public repository to a CST heavy or light chain variable region, heavy or light CDR region or CDR-H3 alone (IMGT-defined). The CSTs are identified by their names in the leftmost column. The entries are sorted from top to bottom by the highest heavy chain identity. An interactive version of this table together with aligned sequences are available at <http://naturalantibody.com/therapeutics>.

CST Name	Best Heavy Chain Identity (%)	Best Light Identity (%)	Best Heavy CDRs Identity (%)	Best Light CDRs Identity (%)	Best CDR-H3 Identity (%)
<i>Enfortumab</i>	98	98	96	100	100
<i>Racotumomab</i>	97	100	90	100	92
<i>Tabalumab</i>	97	99	96	100	100
<i>Emapalumab</i>	97	99	93	95	87
<i>Tremelimumab</i>	97	97	94	94	88
<i>Ascrinvacumab</i>	96	100	96	100	100
<i>Derlotuximab</i>	96	100	89	100	92
<i>Zolbetuximab</i>	96	100	88	100	81
<i>Ganitumab</i>	96	99	92	100	91
<i>Rilotumumab</i>	96	98	93	94	100
<i>Durvalumab</i>	96	98	90	94	92
<i>Patritumab</i>	96	97	92	95	90
<i>Brazikumab</i>	96	96	90	95	94
<i>Carotuximab</i>	95	100	85	100	77
<i>Varlilumab</i>	95	98	89	100	91
<i>Brodalumab</i>	95	96	88	100	100
<i>Futuximab</i>	95	92	87	88	81
<i>Ramucirumab</i>	95	87	100	88	100
<i>Zanolimumab</i>	94	99	100	100	100
<i>Foravirumab</i>	94	98	89	100	100
<i>Dusigitumab</i>	94	97	100	86	100
<i>Rituximab</i>	94	97	90	94	85
<i>Muromonab</i>	94	97	82	100	83
<i>Ublituximab</i>	94	96	96	88	100
<i>Dectrekumab</i>	94	96	93	95	100
<i>Necitumumab</i>	94	95	93	94	92
<i>Cixutumumab</i>	94	94	89	85	82
<i>Fasinumab</i>	94	93	89	88	83
<i>Sifalimumab</i>	93	100	88	100	100
<i>Modotuximab</i>	93	100	82	100	91

<i>Golimumab</i>	93	99	88	94	94
<i>Brentuximab</i>	93	98	96	100	100
<i>Suvratoxumab</i>	93	98	87	94	87
<i>Zalutumumab</i>	93	98	85	100	88
<i>Bavituximab</i>	93	98	82	94	92
<i>Basiliximab</i>	93	97	88	93	90
<i>Radretumab</i>	93	96	80	84	100
<i>Ofatumumab</i>	92	100	90	100	93
<i>Bezlotoxumab</i>	92	100	89	100	91
<i>Daratumumab</i>	92	100	83	100	86
<i>Inclacumab</i>	92	100	75	100	88
<i>Siltuximab</i>	92	99	89	100	91
<i>Canakinumab</i>	92	99	85	100	100
<i>Lirilumab</i>	92	99	84	100	87
<i>Abrilumab</i>	92	97	85	100	90
<i>Tisotumab</i>	92	97	81	100	81
<i>Indusatumab</i>	92	96	82	100	84
<i>Carlumab</i>	92	92	82	70	83
<i>Tovetumab</i>	92	90	86	89	92
<i>Utomilumab</i>	92	89	88	55	100
<i>Tesidolumab</i>	92	87	92	65	100
<i>Glembatumumab</i>	91	99	92	100	100
<i>Ipilimumab</i>	91	99	88	100	90
<i>Iratumumab</i>	91	98	85	100	100
<i>Cetuximab</i>	91	97	82	94	92
<i>Burosumab</i>	91	97	80	94	90
<i>Anifrolumab</i>	91	96	84	89	90
<i>Pritoxaximab</i>	91	96	80	100	80
<i>Seribantumab</i>	91	95	78	95	83
<i>Girentuximab</i>	91	95	78	88	91
<i>Guselkumab</i>	91	94	80	82	90
<i>Lenzilumab</i>	91	91	78	83	83
<i>Abagovomab</i>	91	90	89	94	100
<i>Domagrozumab</i>	91	89	92	100	88
<i>Briakinumab</i>	91	88	87	65	75
<i>Otelixizumab</i>	91	71	82	75	83
<i>Intetumumab</i>	90	100	85	100	91
<i>Icrucumab</i>	90	100	82	100	78
<i>Foralumab</i>	90	100	81	100	90

<i>Fulranumab</i>	90	100	78	100	93
<i>Aducanumab</i>	90	100	78	100	88
<i>Sarilumab</i>	90	99	88	100	100
<i>Bleselumab</i>	90	98	80	100	84
<i>Tezepelumab</i>	90	98	80	100	80
<i>Opicinumab</i>	90	98	77	100	90
<i>Panitumumab</i>	90	97	89	94	90
<i>Tomuzotuximab</i>	90	97	82	94	92
<i>Timolumab</i>	90	97	80	100	100
<i>Adalimumab</i>	90	97	80	94	71
<i>Figitumumab</i>	90	96	91	100	88
<i>Evolocumab</i>	90	96	91	90	100
<i>Berlimatoxumab</i>	90	95	89	83	90
<i>Tralokinumab</i>	90	95	80	85	80
<i>Ensituximab</i>	90	94	81	94	85
<i>Anetumab</i>	90	92	82	73	84
<i>Setrusumab</i>	90	91	84	78	90
<i>Itolizumab</i>	90	90	82	88	83
<i>Ianalumab</i>	90	88	78	73	71
<i>Elotuzumab</i>	90	87	96	100	100
<i>Emibetuzumab</i>	90	87	87	94	100
<i>Evinacumab</i>	89	100	91	100	94
<i>Eldelumab</i>	89	100	81	100	94
<i>Nivolumab</i>	89	100	77	100	100
<i>Avelumab</i>	89	100	75	100	84
<i>Denosumab</i>	89	98	87	100	80
<i>Atidortoxumab</i>	89	98	67	88	83
<i>Setoxaximab</i>	89	96	85	100	91
<i>Drozitumab</i>	89	96	80	90	85
<i>Indatuximab</i>	89	95	87	94	100
<i>Tarextumab</i>	89	94	75	89	75
<i>Amatuximab</i>	89	93	82	94	100
<i>Infliximab</i>	89	93	75	83	90
<i>Lorvatuzumab</i>	89	92	88	86	100
<i>Bimagrumab</i>	89	92	87	73	100
<i>Solanezumab</i>	89	92	80	91	100
<i>Mavrilimumab</i>	89	91	72	73	61
<i>Camrelizumab</i>	89	90	92	88	100
<i>Tigatuzumab</i>	89	87	89	100	83

<i>Anrukinzumab</i>	89	87	85	90	91
<i>Urelumab</i>	88	100	80	100	86
<i>Secukinumab</i>	88	100	80	100	80
<i>Olaratumab</i>	88	100	77	100	78
<i>Erenumab</i>	88	99	71	100	82
<i>Alirocumab</i>	88	96	85	95	90
<i>Gantenerumab</i>	88	94	68	89	63
<i>Orticumab</i>	88	92	73	77	78
<i>Crenezumab</i>	88	91	95	100	100
<i>Concizumab</i>	88	91	80	95	85
<i>Bapineuzumab</i>	88	91	75	100	83
<i>Actoxumab</i>	87	100	83	100	86
<i>Dupilumab</i>	87	97	76	95	72
<i>Rafivirumab</i>	87	95	75	83	70
<i>Margetuximab</i>	87	94	82	94	84
<i>Trevogrumab</i>	87	94	79	88	69
<i>Dinutuximab</i>	87	90	86	95	83
<i>Mirvetuximab</i>	87	90	77	100	90
<i>Olendalizumab</i>	87	88	75	100	92
<i>Quilizumab</i>	87	86	88	91	100
<i>Obiltoxaximab</i>	87	85	100	100	100
<i>Lampalizumab</i>	87	83	79	94	75
<i>Pamrevlumab</i>	86	100	82	100	92
<i>Fletikumab</i>	86	100	80	100	85
<i>Lanadelumab</i>	86	100	67	100	73
<i>Ustekinumab</i>	86	99	78	100	83
<i>Teprotumumab</i>	86	98	85	100	90
<i>Refanezumab</i>	86	96	80	100	73
<i>Galiximab</i>	86	94	58	90	63
<i>Coltuximab</i>	86	92	96	86	100
<i>Ibalizumab</i>	86	92	87	95	80
<i>Isatuximab</i>	86	91	89	94	92
<i>Otlertuzumab</i>	86	90	92	77	88
<i>Rovalpituzumab</i>	86	90	88	94	90
<i>Landogrozumab</i>	86	89	81	89	100
<i>Daclizumab</i>	86	87	92	88	100
<i>Etaracizumab</i>	86	87	84	88	90
<i>Enokizumab</i>	86	87	80	72	86
<i>Robatumumab</i>	86	87	77	100	91

<i>Tislelizumab</i>	86	86	88	83	91
<i>Lacnotuzumab</i>	86	85	88	94	90
<i>Panobacumab</i>	85	100	84	100	80
<i>Fezakinumab</i>	85	96	70	95	71
<i>Fresolimumab</i>	85	95	62	89	84
<i>Romosozumab</i>	85	93	84	100	81
<i>Dalotuzumab</i>	85	91	80	100	90
<i>Imgatuzumab</i>	85	90	68	76	92
<i>Bococizumab</i>	85	89	77	83	81
<i>Atezolizumab</i>	85	89	77	77	90
<i>Visilizumab</i>	85	88	89	100	100
<i>Lodelcizumab</i>	85	88	70	70	90
<i>Lintuzumab</i>	85	87	96	100	100
<i>Bimekizumab</i>	85	84	67	66	66
<i>Veltuzumab</i>	85	82	90	94	92
<i>Rozanolixizumab</i>	85	82	73	82	80
<i>Codrituzumab</i>	84	91	83	91	87
<i>Plozalizumab</i>	84	91	73	100	87
<i>Simtuzumab</i>	84	90	92	100	100
<i>Mogamulizumab</i>	84	88	67	78	75
<i>Tildrakizumab</i>	84	87	92	100	100
<i>Gevokizumab</i>	84	86	79	88	75
<i>Sacituzumab</i>	84	85	96	94	100
<i>Gedivumab</i>	83	93	67	80	55
<i>Obinutuzumab</i>	83	91	78	100	83
<i>Ozanezumab</i>	83	90	90	100	83
<i>Ixekizumab</i>	83	90	78	91	75
<i>Abituzumab</i>	83	89	85	100	90
<i>Trastuzumab</i>	83	89	82	94	84
<i>Etrolizumab</i>	83	89	76	72	100
<i>Ponezumab</i>	83	89	64	78	77
<i>Matuzumab</i>	83	85	83	88	92
<i>Motavizumab</i>	83	85	75	88	83
<i>Inebilizumab</i>	83	84	90	90	92
<i>Lifastuzumab</i>	83	84	65	78	76
<i>Tanezumab</i>	82	91	80	83	86
<i>Olokizumab</i>	82	90	65	72	81
<i>Ocrelizumab</i>	82	88	93	94	93
<i>Sirukumab</i>	82	88	75	82	83

<i>Andecaliximab</i>	82	85	87	77	100
<i>Palivizumab</i>	82	84	86	94	100
<i>Lumiliximab</i>	81	94	59	83	88
<i>Tocilizumab</i>	81	92	82	100	83
<i>Galcanezumab</i>	81	90	75	83	83
<i>Duligotuzumab</i>	81	90	63	77	78
<i>Roledumab</i>	81	89	68	94	73
<i>Vadastuximab</i>	81	88	88	100	100
<i>Vedolizumab</i>	81	88	86	95	85
<i>Mirikizumab</i>	81	88	83	77	87
<i>Natalizumab</i>	81	87	90	100	100
<i>Eculizumab</i>	81	87	83	100	86
<i>Pinatuzumab</i>	81	86	89	86	100
<i>Ficlatuzumab</i>	81	86	81	88	90
<i>Eptinezumab</i>	81	80	70	29	100
<i>Belimumab</i>	80	98	62	100	62
<i>Crizanlizumab</i>	80	91	90	86	93
<i>Depatuxizumab</i>	80	88	76	94	88
<i>Pertuzumab</i>	80	88	75	83	91
<i>Ligelizumab</i>	80	88	71	88	81
<i>Blosozumab</i>	80	88	66	88	81
<i>Ravulizumab</i>	80	87	77	100	86
<i>Fremanezumab</i>	80	87	67	77	53
<i>Clazakizumab</i>	80	87	65	57	78
<i>Pembrolizumab</i>	80	86	86	90	84
<i>Inotuzumab</i>	80	82	80	95	100
<i>Pidilizumab</i>	80	82	76	94	90
<i>Vatelizumab</i>	80	79	82	88	92
<i>Benralizumab</i>	79	89	83	83	71
<i>Certolizumab</i>	79	87	81	100	100
<i>Lebrikizumab</i>	79	85	74	95	91
<i>Epratuzumab</i>	79	84	84	95	88
<i>Satralizumab</i>	79	84	71	72	83
<i>Risankizumab</i>	79	83	82	83	84
<i>Reslizumab</i>	78	89	92	77	100
<i>Onartuzumab</i>	78	85	78	87	75
<i>Farletuzumab</i>	78	82	96	90	100
<i>Bevacizumab</i>	77	93	90	88	93
<i>Vonlerolizumab</i>	77	92	65	94	80

<i>Idarucizumab</i>	77	91	83	95	87
<i>Polatuzumab</i>	77	90	80	95	80
<i>Rontalizumab</i>	77	88	76	95	90
<i>Parsatuzumab</i>	77	86	81	82	93
<i>Gemtuzumab</i>	77	83	80	86	88
<i>Spartalizumab</i>	77	83	76	91	90
<i>Efalizumab</i>	76	94	83	100	85
<i>Alemtuzumab</i>	76	90	80	66	91
<i>Dacetuzumab</i>	76	84	82	91	85
<i>Tregalizumab</i>	76	84	72	100	93
<i>Omalizumab</i>	75	90	76	100	71
<i>Nimotuzumab</i>	75	81	68	95	62
<i>Pateclizumab</i>	74	91	81	88	81
<i>Teplizumab</i>	74	82	82	100	83
<i>Ranibizumab</i>	73	92	81	88	93
<i>Mepolizumab</i>	72	92	78	95	84
<i>Ontuxizumab</i>	69	85	78	84	82